Materiały źródłowe

• #1 Lobular Carcinoma in Situ | LCIS | American Cancer Society

  https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/lobular-carcinoma-in-situ.html

  LCIS is not considered cancer, and it typically does not spread beyond the lobule (that is, it doesn’t become invasive breast cancer) if it isnt treated. […] But having LCIS does increase your risk of later developing an invasive breast cancer in either breast. […] Women with LCIS have about a 7 to 12 times higher risk of developing invasive cancer in either breast. For this reason, doctors typically recommend that women with LCIS have regular breast cancer screening tests and follow-up visits with a health care provider for the rest of their lives. […] Having LCIS does increase your risk of developing invasive breast cancer later on. But since LCIS is not a true cancer or pre-cancer, often no treatment is needed after the biopsy. […] Women should also talk to a health care provider about what they can do to help reduce their breast cancer risk. Options for women at high risk of breast cancer because of LCIS may include: […] Surgery, called bilateral prophylactic mastectomy (removal of both breasts), to reduce risk.

• #2 Lobular Carcinoma in Situ (LCIS) | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/lobular-carcinoma-in-situ/

  Women with LCIS have an increased risk of invasive breast cancer [254-256]. […] Compared to women without LCIS, those with LCIS are 7-11 times more likely to develop invasive cancer in either breast (the breast with LCIS or the opposite breast) [254-255]. […] The National Comprehensive Cancer Network (NCCN) strongly recommends women with LCIS take a risk-reducing drug (such as tamoxifen) to lower their risk of breast cancer [54]. […] Today, the use of a risk-reducing drug (along with recommended breast cancer screening to find breast cancer early if it develops) is the preferred option over risk-reducing mastectomy for lowering risk in women with LCIS [54]. […] In the past, risk-reducing bilateral mastectomy (surgery to remove both breasts) was considered for women with LCIS to lower breast cancer risk as much as possible. This is now discouraged since the risk reduction benefits from a risk-reducing drug and surgery are similar [54].

• #3 Lobular carcinoma in situ (LCIS) – Symptoms & causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/lobular-carcinoma-in-situ/symptoms-causes/syc-20374529

  Lobular carcinoma in situ (LCIS) is an uncommon condition in which abnormal cells form in the milk glands (lobules) in the breast. Lobular carcinoma in situ (LCIS) isn’t cancer. But being diagnosed with LCIS indicates that you have an increased risk of developing breast cancer. […] Women with LCIS have an increased risk of developing invasive breast cancer in either breast. If you’re diagnosed with LCIS, your doctor may recommend increased breast cancer screening and may ask you to consider medical treatments to reduce your risk of developing invasive breast cancer. […] If LCIS is detected in a breast biopsy, it doesn’t mean that you have cancer. But having LCIS increases your risk of breast cancer and makes it more likely that you may develop invasive breast cancer. […] The risk of breast cancer in women diagnosed with LCIS is thought to be approximately 20 percent. Put another way, for every 100 women diagnosed with LCIS, 20 will be diagnosed with breast cancer and 80 won’t be diagnosed with breast cancer. The risk of developing breast cancer for women in general is thought to be 12 percent. Put another way, for every 100 women in the general population, 12 will be diagnosed with breast cancer. […] Your individual risk of breast cancer is based on many factors. Talk to your doctor to better understand your personal risk of breast cancer.

• #4 Understanding Lobular Carcinoma In Situ (LCIS) | Breast Cancer Research Foundation

  https://www.bcrf.org/about-breast-cancer/lcis-lobular-carcinoma-in-situ/

  LCIS is not generally thought to be a precursor to invasive breast cancer. They are more accepted as a marker of increased risk of invasive breast cancer, similar to age or family history. […] The average risk of a woman developing breast cancer in her lifetime is 12 percent. That risk increases to 20 to 30 percent if a woman has been diagnosed with LCIS. The younger a woman is at diagnosis, the higher the risk. […] Because of the elevated cancer risk, doctors may recommend more frequent mammogram, ultrasound, and MRI screenings to ensure any cancer that develops is caught at its earliest stage. Depending on the individual and the LCIS prognosis, they may also recommend hormone therapies that reduce risk, such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs). […] In rare circumstances when a patient’s risk is elevated because of a strong family history of breast cancer or if LCIS is diagnosed at a younger age, a prophylactic bilateral mastectomy, surgery that removes both breasts, may be recommended.

• #5 Recommendations for Women With Lobular Carcinoma In Situ (LCIS)

  https://www.cancernetwork.com/view/recommendations-women-lobular-carcinoma-situ-lcis

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] A diagnosis of LCIS is one of the greatest identifiable risk factors for the subsequent development of breast cancer. Compared to the general population, women with LCIS have an eight-fold to ten-fold increased risk of breast cancer. […] Surveillance is the minimum necessary action for women in whom LCIS is diagnosed. Recommendations from the NCCN Breast Cancer Screening and Diagnosis Clinical Practice Guidelines include annual mammography and clinical breast exam every 6 to 12 months.

• #6 Recommendations for women with lobular carcinoma in situ (LCIS) – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22106556/

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Although LN occurs relatively infrequently, it is associated with an increased risk of breast cancer, ranging from a three- to four-fold increased risk with ALH up to an eight- to ten-fold increased risk with LCIS. […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. […] As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] Paralleling changes in the management of invasive breast cancer, trends in the management of LCIS have moved toward more conservative management. […] However, we have made little progress in understanding the biology of LCIS and therefore remain unable to truly optimize recommendations for individual patients.

• #7 Lobular carcinoma in situ (LCIS) | Beacon Health System

  https://www.beaconhealthsystem.org/library/diseases-and-conditions/lobular-carcinoma-in-situ-lcis?content_id=CON-20374514

  If a breast biopsy reveals you have LCIS, your risk of breast cancer is increased. Learn how you can reduce your risk through medications and other strategies. […] If you’re diagnosed with LCIS, your doctor may recommend increased breast cancer screening and may ask you to consider medical treatments to reduce your risk of developing invasive breast cancer. […] Preventive therapy (chemoprevention) involves taking a medication to reduce your risk of breast cancer. […] Discuss with your doctor the risks and benefits of taking a drug for breast cancer prevention to see if it’s the best course of treatment for you. […] Another option for treating LCIS is preventive (prophylactic) mastectomy. This surgery removes both breasts not just the breast affected with LCIS to reduce your risk of developing invasive breast cancer.

• #8 Lobular Carcinoma in Situ (LCIS) – Iowa Radiology

  https://www.iowaradiology.com/lobular-carcinoma-in-situ-lcis/

  Lobular carcinoma in situ (LCIS) describes the growth of abnormal cells in the breast lobules, the milk-producing glands at the ends of the milk ducts. In situ means that the abnormal cells are contained in their original place and have not invaded the surrounding tissue. […] Because the presence of LCIS indicates an elevated breast cancer risk, it is especially important that patients with the condition continue to get regular screening mammograms. […] Some patients with LCIS choose to take medications to lower their risk of developing breast cancer (called chemoprevention). […] LCIS patients at higher risk, such as those with a family history of breast cancer or BRCA gene mutation, may choose surgery to control their risk. Sometimes only the affected tissue is surgically removed; in that case, follow-up examinations are important because the patient will still be at higher than average risk of breast cancer. Some women with high breast cancer risk choose to undergo prophylactic mastectomy, in which both breasts are removed as a preventive measure.

• #9 Lobular Carcinoma in Situ (LCIS)

  https://info.iowaradiology.com/lobular-carcinoma-in-situ-lcis

  Lobular carcinoma in situ (LCIS) describes the growth of abnormal cells in the breast lobules, the milk-producing glands at the ends of the milk ducts. In situ means that the abnormal cells are contained in their original place and have not invaded the surrounding tissue. […] Unlike ductal carcinoma in situ (DCIS), LCIS is not considered true breast cancer. Rather, it is a condition that is associated with an increased risk of developing breast cancer in the future. Because of this, some experts prefer the term lobular neoplasia (denoting the development of abnormal lobular cells) rather than referring to this condition as carcinoma. Women with LCIS have 8-10 times the average risk of developing invasive breast cancer in either the lobules or the milk ducts. […] Because the presence of LCIS indicates an elevated breast cancer risk, it is especially important that patients with the condition continue to get regular screening mammograms. The American Cancer Society and the National Comprehensive Cancer Network offer these guidelines for LCIS patients to ensure that any breast cancer that may develop is caught as early as possible: Get clinical breast exams every 6-12 months. Get annual screening mammograms. Talk to your doctor about regular screening using breast MRI.

• #10 Lobular Carcinoma in Situ – Cancer Specialists of Tidewater

  https://tidewatercancer.com/types-of-cancer/breast-cancer/carcinoma-in-situ/lobular-carcinoma-in-situ/

  The treatment of lobular carcinoma in situ (LCIS) is somewhat controversial. LCIS is thought to be an indicator for an increased risk of developing invasive breast cancer, but may not be a direct precursor to invasive breast cancer. […] Current approaches for management of LCIS include surgical removal of the LCIS or treatment with anti-estrogens to reduce the risk of developing invasive cancer. […] Observation is a generally accepted form of management for patients with LCIS. […] Because of the observation that women with breast cancer treated with Nolvadex had a lower risk of developing a new breast cancer in their unaffected breast, many doctors felt that Nolvadex may actually be able to prevent breast cancer from occurring. […] In patients with LCIS, the incidence of invasive breast cancer was reduced 56% by the administration of Nolvadex.

• #11 Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis | CoLab

  https://colab.ws/articles/10.1002%2Fcncr.30644

  Women diagnosed with lobular carcinoma in situ (LCIS) have a 3-fold to 10-fold increased risk of developing invasive breast cancer. […] The objective of this study was to evaluate the life expectancy (LE) and differences in survival offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy among women with LCIS. […] In this model, among women with a diagnosis of LCIS, breast cancer prevention strategies only modestly affected overall survival, whereas chemoprevention was modeled as the preferred management strategy for optimizing invasive disease-free survival while prolonging QALE for women younger than 65 years.

• #12 Lobular Carcinoma in Situ (LCIS) | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/lobular-carcinoma-in-situ/

  Women with LCIS have an increased risk of invasive breast cancer [254-256]. […] Compared to women without LCIS, those with LCIS are 7-11 times more likely to develop invasive cancer in either breast (the breast with LCIS or the opposite breast) [254-255]. […] The National Comprehensive Cancer Network (NCCN) strongly recommends women with LCIS take a risk-reducing drug (such as tamoxifen) to lower their risk of breast cancer [54]. […] Today, the use of a risk-reducing drug (along with recommended breast cancer screening to find breast cancer early if it develops) is the preferred option over risk-reducing mastectomy for lowering risk in women with LCIS [54]. […] In the past, risk-reducing bilateral mastectomy (surgery to remove both breasts) was considered for women with LCIS to lower breast cancer risk as much as possible. This is now discouraged since the risk reduction benefits from a risk-reducing drug and surgery are similar [54].

• #13 Lobular Carcinoma in Situ – Cancer Specialists of Tidewater

  https://tidewatercancer.com/types-of-cancer/breast-cancer/carcinoma-in-situ/lobular-carcinoma-in-situ/

  The treatment of lobular carcinoma in situ (LCIS) is somewhat controversial. LCIS is thought to be an indicator for an increased risk of developing invasive breast cancer, but may not be a direct precursor to invasive breast cancer. […] Current approaches for management of LCIS include surgical removal of the LCIS or treatment with anti-estrogens to reduce the risk of developing invasive cancer. […] Observation is a generally accepted form of management for patients with LCIS. […] Because of the observation that women with breast cancer treated with Nolvadex had a lower risk of developing a new breast cancer in their unaffected breast, many doctors felt that Nolvadex may actually be able to prevent breast cancer from occurring. […] In patients with LCIS, the incidence of invasive breast cancer was reduced 56% by the administration of Nolvadex.

• #14 Lobular Carcinoma in Situ – Virginia Cancer Institute

  https://www.vacancer.com/cancer/breast-cancer/carcinoma-in-situ/lobular-carcinoma-in-situ/

  The treatment of lobular carcinoma in situ (LCIS) is somewhat controversial. […] Current approaches for management of LCIS include surgical removal of the LCIS or treatment with anti-estrogens to reduce the risk of developing invasive cancer. […] Observation is a generally accepted form of management for patients with LCIS. […] Because of the observation that women with breast cancer treated with Nolvadex had a lower risk of developing a new breast cancer in their unaffected breast, many doctors felt that Nolvadex may actually be able to prevent breast cancer from occurring. […] In patients with LCIS, the incidence of invasive breast cancer was reduced 56% by the administration of Nolvadex. […] Based on the results of this clinical study, the Food and Drug Administration concluded that Nolvadex should be approved for reducing the risk of breast cancer in women at high risk of developing breast cancer. […] All patients with LCIS may want to consider treatment intervention with Nolvadex or other anti-estrogens. […] A bilateral prophylactic mastectomy involves the preventive removal of both breasts. This is an effective method of preventing invasive breast cancer in patients with LCIS.

• #15 Stage 0 Breast Cancer (DCIS, LCIS) – Cancer Therapy Advisor

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/oncology/stage-0-breast-cancer-dcis-lcis/

  The medical approach to LCIS is that of chemoprevention. Randomized clinical trials of chemoprevention in women at high risk for breast cancer have shown reduction in risk of invasive breast cancer for women with LCIS. In the NSABP Breast Cancer Prevention Trial-BCPT, tamoxifen reduced the risk of invasive cancer by 50% compared to placebo in those whose increased risk was due to LCIS. […] In the subsequent STAR trial, comparing tamoxifen to raloxifene in high-risk women, raloxifene was also found to be efficacious. However, in longer term follow-up, raloxifene was only 75% as effective as tamoxifen in reducing risk of breast cancer. […] In 2011, a study of chemoprevention with an aromatase inhibitor, exemestane was reported. In a median follow-up of 3 years, breast cancer events were reduced by over 50% with exemestane compared to placebo. The risk of invasive breast cancer was reduced by 65%.

• #16 Stage 0 Breast Cancer (DCIS, LCIS) – Cancer Therapy Advisor

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/oncology/stage-0-breast-cancer-dcis-lcis/

  The medical approach to LCIS is that of chemoprevention. Randomized clinical trials of chemoprevention in women at high risk for breast cancer have shown reduction in risk of invasive breast cancer for women with LCIS. In the NSABP Breast Cancer Prevention Trial-BCPT, tamoxifen reduced the risk of invasive cancer by 50% compared to placebo in those whose increased risk was due to LCIS. […] In the subsequent STAR trial, comparing tamoxifen to raloxifene in high-risk women, raloxifene was also found to be efficacious. However, in longer term follow-up, raloxifene was only 75% as effective as tamoxifen in reducing risk of breast cancer. […] In 2011, a study of chemoprevention with an aromatase inhibitor, exemestane was reported. In a median follow-up of 3 years, breast cancer events were reduced by over 50% with exemestane compared to placebo. The risk of invasive breast cancer was reduced by 65%.

• #17 Breast cancer in situ – Symptoms, diagnosis and treatment | BMJ Best Practice US

  https://bestpractice.bmj.com/topics/en-us/717

  Breast cancer in situ comprises ductal carcinoma in situ (DCIS), a noninvasive breast cancer that is confined to the duct in which it originates, and lobular carcinoma in situ (LCIS). […] Chemoprophylaxis (e.g., with tamoxifen, raloxifene, or an aromatase inhibitor [anastrozole or exemestane]) can be used in high-risk patients. Some high-risk patients may choose to undergo preventive bilateral total mastectomy. […] LCIS is not cancer but a pathologic description of a neoplastic proliferation of cells within lobules and/or terminal ducts, which is a risk factor for invasive breast cancer. […] A finding of LCIS does not imply that cancer will form at the diagnostic site. Consequently, treatment for LCIS is less formalized than for DCIS.

• #18 Lobular Carcinoma in Situ (LCIS) | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/lobular-carcinoma-in-situ/

  Women with LCIS have an increased risk of invasive breast cancer [254-256]. […] Compared to women without LCIS, those with LCIS are 7-11 times more likely to develop invasive cancer in either breast (the breast with LCIS or the opposite breast) [254-255]. […] The National Comprehensive Cancer Network (NCCN) strongly recommends women with LCIS take a risk-reducing drug (such as tamoxifen) to lower their risk of breast cancer [54]. […] Today, the use of a risk-reducing drug (along with recommended breast cancer screening to find breast cancer early if it develops) is the preferred option over risk-reducing mastectomy for lowering risk in women with LCIS [54]. […] In the past, risk-reducing bilateral mastectomy (surgery to remove both breasts) was considered for women with LCIS to lower breast cancer risk as much as possible. This is now discouraged since the risk reduction benefits from a risk-reducing drug and surgery are similar [54].

• #19 Lobular Carcinoma in Situ (LCIS)

  https://info.iowaradiology.com/lobular-carcinoma-in-situ-lcis

  Some patients with LCIS choose to take medications to lower their risk of developing breast cancer (called chemoprevention). A recent study found that women with LCIS have a 2% annual risk of developing breast cancer, and those who choose chemoprevention lower that annual risk to below 1%. The two drugs approved by the FDA for this purpose are tamoxifen and raloxifene. […] LCIS patients at higher risk, such as those with a family history of breast cancer or BRCA gene mutation, may choose surgery to control their risk. Sometimes only the affected tissue is surgically removed; in that case, follow-up examinations are important because the patient will still be at higher than average risk of breast cancer. Some women with high breast cancer risk choose to undergo prophylactic mastectomy, in which both breasts are removed as a preventive measure. It’s important to discuss all of your risk factors and treatment options with your doctor.

• #20 LCIS blog- preventative bi-lateral mastectomy – Page 5 — Community Discussion Forums

  https://community.breastcancer.org/en/discussion/761364/lcis-blog-preventative-bi-lateral-mastectomy/p5

  I honestly can still say that I think it was the best decision for me as I watch some of my close friends and family cope with the pain of chemo and other drugs. […] I would also suggest getting your body in good condition with exercise before you undergo the surgeries since a healthy body is easier to heal…especially when we are older. […] I think the picture is more clouded for LCIS. […] Treatment is a very individual choice. I will not challenge anyone’s choice as to what treatment is best for them. […] Chemoprevention should only be considered after an informed discussion of the risks versus the benefits.

• #21 Lobular carcinoma in situ (LCIS) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/lobular-carcinoma-in-situ/diagnosis-treatment/drc-20374535

  Lobular carcinoma in situ (LCIS) may be present in one or both breasts, but it usually isn’t visible on a mammogram. […] A number of factors, including your personal preferences, come into play when you decide whether to undergo treatment for lobular carcinoma in situ (LCIS). […] Preventive therapy (chemoprevention) involves taking a medication to reduce your risk of breast cancer. […] Discuss with your doctor the risks and benefits of taking a drug for breast cancer prevention to see if it’s the best course of treatment for you. […] Another option for treating LCIS is preventive (prophylactic) mastectomy. This surgery removes both breasts not just the breast affected with LCIS to reduce your risk of developing invasive breast cancer. […] If you’re worried about your risk of breast cancer, take steps to reduce your risk, such as: […] Although LCIS is not cancer, it can make you worry about your increased risk of a future breast cancer.

• #22 Recommendations for women with lobular carcinoma in situ (LCIS) – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22106556/

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Although LN occurs relatively infrequently, it is associated with an increased risk of breast cancer, ranging from a three- to four-fold increased risk with ALH up to an eight- to ten-fold increased risk with LCIS. […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. […] As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] Paralleling changes in the management of invasive breast cancer, trends in the management of LCIS have moved toward more conservative management. […] However, we have made little progress in understanding the biology of LCIS and therefore remain unable to truly optimize recommendations for individual patients.

• #23 Lobular Carcinoma in Situ: Symptoms, Causes, Treatment | Qwark

  https://qwarkhealth.com/conditions/lobular-carcinoma-in-situ

  Lobular Carcinoma in Situ (LCIS) is a condition that occurs when abnormal cells are present in the milk-producing glands of a woman`s breast. […] Women with LCIS are often advised to undergo more frequent mammograms, breast exams, and other cancer screening tests to detect any changes in their breast tissue. […] Treatment for LCIS is typically not necessary, but some women choose to have a prophylactic mastectomy, where both breasts are surgically removed to reduce their risk of developing breast cancer in the future. […] The surgical options include prophylactic mastectomy, breast-conserving surgery, and bilateral salpingo-oophorectomy. Women who undergo a prophylactic mastectomy can reduce their risk of developing breast cancer by more than 90%. […] The treatment of LCIS is focused on reducing the risk of developing invasive cancer in the future by closely monitoring the patient and using preventive measures like hormone therapy or prophylactic mastectomy.

• #24 Recommendations for Women With Lobular Carcinoma In Situ (LCIS)

  https://www.cancernetwork.com/view/recommendations-women-lobular-carcinoma-situ-lcis

  Collectively, these data led to a statement from the American Society of Clinical Oncology (ASCO) recommending 5 years of tamoxifen for high-risk premenopausal women to reduce the risk of estrogen receptor (ER)-positive invasive breast cancer, and raloxifene to reduce risk for postmenopausal women. […] Nevertheless, BPM may be a reasonable option for a subset of women with LCIS and other risk factors, such as a strong family history or extremely dense breasts. […] The decision to undergo BPM is highly individual and should not be undertaken without ample time to consider all of the available options for risk management.

• #25 Lobular carcinoma in situ (LCIS) | Altru Health System

  https://www.altru.org/health-library/conditions/lobular-carcinoma-in-situ-lcis

  Another option for treating LCIS is preventive (prophylactic) mastectomy. This surgery removes both breasts not just the breast affected with LCIS to reduce your risk of developing invasive breast cancer. To obtain the best possible protective benefit from this surgery, both breasts are removed, because LCIS increases your risk of developing breast cancer in either breast. This may be an option if you have additional risk factors for breast cancer, such as an inherited gene mutation that increases your risk, or a very strong family history of the disease.

• #26 Lobular Carcinoma in Situ (LCIS) | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/lobular-carcinoma-in-situ/

  Women with LCIS have an increased risk of invasive breast cancer [254-256]. […] Compared to women without LCIS, those with LCIS are 7-11 times more likely to develop invasive cancer in either breast (the breast with LCIS or the opposite breast) [254-255]. […] The National Comprehensive Cancer Network (NCCN) strongly recommends women with LCIS take a risk-reducing drug (such as tamoxifen) to lower their risk of breast cancer [54]. […] Today, the use of a risk-reducing drug (along with recommended breast cancer screening to find breast cancer early if it develops) is the preferred option over risk-reducing mastectomy for lowering risk in women with LCIS [54]. […] In the past, risk-reducing bilateral mastectomy (surgery to remove both breasts) was considered for women with LCIS to lower breast cancer risk as much as possible. This is now discouraged since the risk reduction benefits from a risk-reducing drug and surgery are similar [54].

• #27 Get Lobular Carcinoma in Situ Treatment | Cleveland Clinic

  https://my.clevelandclinic.org/services/lobular-carcinoma-situ-treatment

  You just found out you may have lobular carcinoma in situ. And now youre worried. Isnt that breast cancer? […] No, but its a red flag. It means you have abnormal cells in your breasts milk glands (lobules). The cells arent spreading or multiplying yet. Theyre in situ, which means theyre staying put for now. But having them means youre at a higher risk of developing breast cancer than people who dont. […] Our team of breast health experts will help you keep an eye on whats happening and manage your condition to lower your risk of getting breast cancer down the road. […] Its important to note that risk-reducing surgery (preventive mastectomy) is no longer the treatment of choice for LCIS, since preventive medications are so effective. […] If youre younger, have a family history of breast cancer or dont respond well to medications, your provider may go over the possibility of risk-reducing surgery with you.

• #28 Lobular Carcinoma in Situ: Symptoms, Causes, Treatment | Qwark

  https://qwarkhealth.com/conditions/lobular-carcinoma-in-situ

  Lifestyle changes that can help prevent the development of LCIS include maintaining a healthy weight, avoiding alcohol consumption, and exercising regularly. […] Women can also reduce their risk of LCIS by breastfeeding for at least six months, avoiding or limiting hormone replacement therapy (HRT), and getting regular mammograms to detect any changes in breast tissue. […] Hormone therapy reduces the chances of developing LCIS by blocking the effects of estrogen in the body. […] There are certain medications that can reduce the risk of LCIS, such as tamoxifen and raloxifene. […] Regular exercise can help prevent LCIS from developing by reducing the levels of estrogen in the body.

• #29 Lobular carcinoma in situ (LCIS) – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/lobular-carcinoma-in-situ/diagnosis-treatment/drc-20374535

  Lobular carcinoma in situ (LCIS) may be present in one or both breasts, but it usually isn’t visible on a mammogram. […] A number of factors, including your personal preferences, come into play when you decide whether to undergo treatment for lobular carcinoma in situ (LCIS). […] Preventive therapy (chemoprevention) involves taking a medication to reduce your risk of breast cancer. […] Discuss with your doctor the risks and benefits of taking a drug for breast cancer prevention to see if it’s the best course of treatment for you. […] Another option for treating LCIS is preventive (prophylactic) mastectomy. This surgery removes both breasts not just the breast affected with LCIS to reduce your risk of developing invasive breast cancer. […] If you’re worried about your risk of breast cancer, take steps to reduce your risk, such as: […] Although LCIS is not cancer, it can make you worry about your increased risk of a future breast cancer.

• #30 Lobular Carcinoma in Situ (LCIS) – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/lobular-carcinoma-in-situ-lcis/

  Lobular carcinoma in situ (LCIS) is a noninvasive precancer. […] For this reason, LCIS doesnt call for an immediate decision. There is no rush to begin treatment. […] The National Comprehensive Cancer Network treatment guidelines recommend close follow-up for women with LCIS. […] Another option is to take tamoxifen or raloxifene (Evista) for five years to reduce your risk of developing breast cancer. […] The most drastic option is bilateral prophylactic mastectomy. […] If you have a family history of breast cancer in addition to LCIS and you want to understand more about whether your family history may contribute to your breast cancer risk, you should make an appointment with a genetic counselor to discuss testing for the hereditary breast cancer gene mutations, called BRCA1 and BRCA2, which put women at higher risk for breast and ovarian cancer. […] If you decide to have genetic testing and are found to carry a BRCA genetic mutation, it may influence your treatment decisions. […] The most important thing to remember is that a diagnosis of LCIS is not an emergency and you should give yourself time to figure out what to do.

• #31 Lobular Carcinoma in Situ (LCIS)

  https://www.cancercenter.com/cancer-types/breast-cancer/risk-factors/lobular-carcinoma-in-situ

  Lobular carcinoma in situ, also known as LCIS, is a medical condition that causes abnormal cells to grow in the breast glands that are responsible for producing milk, known as the lobules. […] LCIS isnt cancer but having the condition may increase the risk of developing invasive breast cancer in the future. According to the American Cancer Society, the risk of invasive breast cancer is seven to 12 times higher if someone was previously diagnosed with LCIS, which is why regular screenings are important. […] Because LCIS isnt a type of cancer, active treatment isnt typically needed. Treatment may also depend on the patients personal preferences. […] Hormone medication may be recommended as a preventative therapy to lower the risk of cancer in the future. […] Increased observation and monitoring may be recommended, so if breast cancer does develop, it may be caught early. […] Patients may also speak to their care team about lifestyle changes they can make to lower the risk of breast cancer. These may include: […] Undergoing genetic testing to help better understand risk level, if the patient has a family history of breast cancer.

• #32 Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis | CoLab

  https://colab.ws/articles/10.1002%2Fcncr.30644

  Women diagnosed with lobular carcinoma in situ (LCIS) have a 3-fold to 10-fold increased risk of developing invasive breast cancer. […] The objective of this study was to evaluate the life expectancy (LE) and differences in survival offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy among women with LCIS. […] In this model, among women with a diagnosis of LCIS, breast cancer prevention strategies only modestly affected overall survival, whereas chemoprevention was modeled as the preferred management strategy for optimizing invasive disease-free survival while prolonging QALE for women younger than 65 years.

• #33 Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis | CoLab

  https://colab.ws/articles/10.1002%2Fcncr.30644

  Women diagnosed with lobular carcinoma in situ (LCIS) have a 3-fold to 10-fold increased risk of developing invasive breast cancer. […] The objective of this study was to evaluate the life expectancy (LE) and differences in survival offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy among women with LCIS. […] In this model, among women with a diagnosis of LCIS, breast cancer prevention strategies only modestly affected overall survival, whereas chemoprevention was modeled as the preferred management strategy for optimizing invasive disease-free survival while prolonging QALE for women younger than 65 years.

• #34 Lobular Carcinoma in Situ (LCIS) | Susan G. Komen®

  https://www.komen.org/breast-cancer/risk-factor/lobular-carcinoma-in-situ/

  Women with LCIS have an increased risk of invasive breast cancer [254-256]. […] Compared to women without LCIS, those with LCIS are 7-11 times more likely to develop invasive cancer in either breast (the breast with LCIS or the opposite breast) [254-255]. […] The National Comprehensive Cancer Network (NCCN) strongly recommends women with LCIS take a risk-reducing drug (such as tamoxifen) to lower their risk of breast cancer [54]. […] Today, the use of a risk-reducing drug (along with recommended breast cancer screening to find breast cancer early if it develops) is the preferred option over risk-reducing mastectomy for lowering risk in women with LCIS [54]. […] In the past, risk-reducing bilateral mastectomy (surgery to remove both breasts) was considered for women with LCIS to lower breast cancer risk as much as possible. This is now discouraged since the risk reduction benefits from a risk-reducing drug and surgery are similar [54].

• #35 Recommendations for Women With Lobular Carcinoma In Situ (LCIS)

  https://www.cancernetwork.com/view/recommendations-women-lobular-carcinoma-situ-lcis

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] A diagnosis of LCIS is one of the greatest identifiable risk factors for the subsequent development of breast cancer. Compared to the general population, women with LCIS have an eight-fold to ten-fold increased risk of breast cancer. […] Surveillance is the minimum necessary action for women in whom LCIS is diagnosed. Recommendations from the NCCN Breast Cancer Screening and Diagnosis Clinical Practice Guidelines include annual mammography and clinical breast exam every 6 to 12 months.

• #36 Recommendations for Women With Lobular Carcinoma In Situ (LCIS)

  https://www.cancernetwork.com/view/recommendations-women-lobular-carcinoma-situ-lcis

  Collectively, these data led to a statement from the American Society of Clinical Oncology (ASCO) recommending 5 years of tamoxifen for high-risk premenopausal women to reduce the risk of estrogen receptor (ER)-positive invasive breast cancer, and raloxifene to reduce risk for postmenopausal women. […] Nevertheless, BPM may be a reasonable option for a subset of women with LCIS and other risk factors, such as a strong family history or extremely dense breasts. […] The decision to undergo BPM is highly individual and should not be undertaken without ample time to consider all of the available options for risk management.

• #37 Lobular Carcinoma in situ (LCIS) in Dallas, TX | Dallas Surgical GroupAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://dallassurgicalgroup.com/lobular-carcinoma-in-situ-lcis/

  LCIS does not develop into cancer itself, however, there is a ~25% risk of developing breast cancer in either breast over 30 years. Most of the cancers that do develop are ductal carcinoma (not invasive lobular carcinoma) and it can occur in any area of the breast. This means that there is no reason to try and remove all of it surgically. Therefore, the approach to LCIS is the same as for any woman who is at high risk – prevention of breast cancer. […] Prophylactic mastectomy is a viable option and will reduce the risk of developing breast cancer by at least 90%. Tamoxifen or raloxifene has been shown in a large study to reduce the chance of getting breast cancer by ~50%. The prevention study was not without side effects, however, and anyone considering this approach should weigh the risks and benefits for her age. Close follow up means having breast exams every six months and annual mammograms. There is no urgency to your decision regarding treatment of LCIS, as the risk stretches out over thirty years and does not begin immediately. Which path you choose will depend on your age, health, and values.

• #38 Lobular Carcinoma in Situ (LCIS) – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/lobular-carcinoma-in-situ-lcis/

  Lobular carcinoma in situ (LCIS) is a noninvasive precancer. […] For this reason, LCIS doesnt call for an immediate decision. There is no rush to begin treatment. […] The National Comprehensive Cancer Network treatment guidelines recommend close follow-up for women with LCIS. […] Another option is to take tamoxifen or raloxifene (Evista) for five years to reduce your risk of developing breast cancer. […] The most drastic option is bilateral prophylactic mastectomy. […] If you have a family history of breast cancer in addition to LCIS and you want to understand more about whether your family history may contribute to your breast cancer risk, you should make an appointment with a genetic counselor to discuss testing for the hereditary breast cancer gene mutations, called BRCA1 and BRCA2, which put women at higher risk for breast and ovarian cancer. […] If you decide to have genetic testing and are found to carry a BRCA genetic mutation, it may influence your treatment decisions. […] The most important thing to remember is that a diagnosis of LCIS is not an emergency and you should give yourself time to figure out what to do.

• #39 Risk of second breast cancers after lobular carcinoma in situ according to hormone receptor status | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176417

  Of the 10,304 women with primary LCIS included in this study, 9949 (96.5%) patients had HR+ tumors, and 355 (3.5%) had HR- tumors. […] This population-based study demonstrated that the risk of second breast cancers was significantly increased in women with HR- first LCIS compared to those with HR+ LCIS. These findings warrant intensive surveillance for second breast cancers in HR- LCIS survivors. […] Modern management of LCIS includes surveillance, risk reduction via chemoprevention, and bilateral prophylactic mastectomy. […] Although subsequent breast cancer risk after primary lobular carcinoma in situ (LCIS) has been studied intensively, whether the risk of second breast cancer after first LCIS varies with hormone receptor (HR) status of primary tumor remains unclear. […] These findings expand the limited body of literature on the risk of second breast cancers after primary LCIS because the current study is the first report using SEER data quantified risks of subsequent breast cancers among LCIS survivors according to HR status of primary LCIS. […] In conclusion, our finding that women with a first primary HR- LCIS have significantly elevated risk of developing second breast cancers has important implications for routine clinical management. HR- LCIS women may also need chemoprevention and more intensive post-treatment follow-up.

• #40 Lobular Carcinoma in Situ of the Breast | Oncohema Key

  https://oncohemakey.com/lobular-carcinoma-in-situ-of-the-breast/

  It is possible that some subgroups of LCIS may exhibit a more aggressive unilateral biology and preinvasive behavior. […] The extent of LCIS (few lobules vs. extensive disease) and subtyping based on classic versus pleomorphic histopathology has not always been a standard part of pathology reports. […] On average, they found a 2% annual incidence of breast cancer development in the setting of a prior diagnosis of LCIS. […] The purposes of this chapter are to define the historical background that led to our current understanding of LCIS biology, delineate histopathologic features of classic and pleomorphic LCIS, discuss the clinical presentation and natural history of LCIS, examine the evidence for and against routine surgical excision after the diagnosis of LCIS on image-guided sampling, review the role for chemoprevention in LCIS management, and discuss the role of surgical prophylaxis for LCIS in the small subgroup of patients for whom it may be appropriate.

• #41 Lobular Carcinoma in Situ (LCIS) – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/lobular-carcinoma-in-situ-lcis/

  Lobular carcinoma in situ (LCIS) is a noninvasive precancer. […] For this reason, LCIS doesnt call for an immediate decision. There is no rush to begin treatment. […] The National Comprehensive Cancer Network treatment guidelines recommend close follow-up for women with LCIS. […] Another option is to take tamoxifen or raloxifene (Evista) for five years to reduce your risk of developing breast cancer. […] The most drastic option is bilateral prophylactic mastectomy. […] If you have a family history of breast cancer in addition to LCIS and you want to understand more about whether your family history may contribute to your breast cancer risk, you should make an appointment with a genetic counselor to discuss testing for the hereditary breast cancer gene mutations, called BRCA1 and BRCA2, which put women at higher risk for breast and ovarian cancer. […] If you decide to have genetic testing and are found to carry a BRCA genetic mutation, it may influence your treatment decisions. […] The most important thing to remember is that a diagnosis of LCIS is not an emergency and you should give yourself time to figure out what to do.

• #42 Lobular Carcinoma in situ (LCIS) in Dallas, TX | Dallas Surgical GroupAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://dallassurgicalgroup.com/lobular-carcinoma-in-situ-lcis/

  LCIS does not develop into cancer itself, however, there is a ~25% risk of developing breast cancer in either breast over 30 years. Most of the cancers that do develop are ductal carcinoma (not invasive lobular carcinoma) and it can occur in any area of the breast. This means that there is no reason to try and remove all of it surgically. Therefore, the approach to LCIS is the same as for any woman who is at high risk – prevention of breast cancer. […] Prophylactic mastectomy is a viable option and will reduce the risk of developing breast cancer by at least 90%. Tamoxifen or raloxifene has been shown in a large study to reduce the chance of getting breast cancer by ~50%. The prevention study was not without side effects, however, and anyone considering this approach should weigh the risks and benefits for her age. Close follow up means having breast exams every six months and annual mammograms. There is no urgency to your decision regarding treatment of LCIS, as the risk stretches out over thirty years and does not begin immediately. Which path you choose will depend on your age, health, and values.

• #43 Recommendations for women with lobular carcinoma in situ (LCIS) – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22106556/

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Although LN occurs relatively infrequently, it is associated with an increased risk of breast cancer, ranging from a three- to four-fold increased risk with ALH up to an eight- to ten-fold increased risk with LCIS. […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. […] As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] Paralleling changes in the management of invasive breast cancer, trends in the management of LCIS have moved toward more conservative management. […] However, we have made little progress in understanding the biology of LCIS and therefore remain unable to truly optimize recommendations for individual patients.

• #44 The Challenges of Treating Lobular Carcinoma In Situ

  https://www.cancernetwork.com/view/challenges-treating-lobular-carcinoma-situ

  Broadly stated, there are two main areas of research that could help refine the current management of LCIS. The first is development of the ability to define at diagnosis those LCIS lesions that are precursor lesions and that are likely to progress to invasive lobular cancers. […] The second research area involves the generation of risk estimates for invasive breast cancer among younger women diagnosed with LCIS. […] Lastly, it appears that the potential benefit of chemoprevention agents such as tamoxifen in women with LCIS has been underappreciated. […] Therefore, in women with LCIS, physicians should consider recommending tamoxifen in those who are premenopausal but post-childbearing and in those who are postmenopausal; they should also consider recommending exemestane (after it is FDA-approved) in postmenopausal women, provided they have no contraindications to therapy. […] Therefore, a woman’s risk should be reassessed periodically so that decisions regarding screening and risk-reduction approaches can be optimized.

• #45 The Challenges of Treating Lobular Carcinoma In Situ

  https://www.cancernetwork.com/view/challenges-treating-lobular-carcinoma-situ

  Broadly stated, there are two main areas of research that could help refine the current management of LCIS. The first is development of the ability to define at diagnosis those LCIS lesions that are precursor lesions and that are likely to progress to invasive lobular cancers. […] The second research area involves the generation of risk estimates for invasive breast cancer among younger women diagnosed with LCIS. […] Lastly, it appears that the potential benefit of chemoprevention agents such as tamoxifen in women with LCIS has been underappreciated. […] Therefore, in women with LCIS, physicians should consider recommending tamoxifen in those who are premenopausal but post-childbearing and in those who are postmenopausal; they should also consider recommending exemestane (after it is FDA-approved) in postmenopausal women, provided they have no contraindications to therapy. […] Therefore, a woman’s risk should be reassessed periodically so that decisions regarding screening and risk-reduction approaches can be optimized.

• #46 Lobular carcinoma in situ (LCIS) | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/lobular-carcinoma-in-situ-lcis

  LCIS is not a cancer. […] Although LCIS isn’t cancer, it means that you have a small increased risk of getting invasive breast cancer in either breast in the future. […] You usually have regular monitoring. In some situations, your doctor may offer you hormone therapy or surgery to keep your risk of developing invasive breast cancer low. […] Your doctor may suggest taking hormone therapy for 5 years to lower your risk of developing invasive breast cancer. This is known as chemo prevention. […] Researchers are also looking into using different types of hormone therapy to prevent invasive breast cancer after a diagnosis of LCIS. […] Results showed that taking hormone therapy for 5 years did reduce the risk of developing breast cancer if you are at high risk of developing it.

• #47 Recommendations for women with lobular carcinoma in situ (LCIS) – PubMed

  https://pubmed.ncbi.nlm.nih.gov/22106556/

  Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) represent a spectrum of breast disease referred to as „lobular neoplasia” (LN). […] Although LN occurs relatively infrequently, it is associated with an increased risk of breast cancer, ranging from a three- to four-fold increased risk with ALH up to an eight- to ten-fold increased risk with LCIS. […] Today, a diagnosis of LCIS remains one of the greatest identifiable risk factors for the subsequent development of breast cancer. […] As such, patients are offered one of three options: (1) lifelong surveillance with the goal of detecting subsequent malignancy at an early stage; (2) chemoprevention; or (3) bilateral prophylactic mastectomy. […] Paralleling changes in the management of invasive breast cancer, trends in the management of LCIS have moved toward more conservative management. […] However, we have made little progress in understanding the biology of LCIS and therefore remain unable to truly optimize recommendations for individual patients.

• #48 Lobular Carcinoma in Situ – Cancer Specialists of Tidewater

  https://tidewatercancer.com/types-of-cancer/breast-cancer/carcinoma-in-situ/lobular-carcinoma-in-situ/

  The treatment of lobular carcinoma in situ (LCIS) is somewhat controversial. LCIS is thought to be an indicator for an increased risk of developing invasive breast cancer, but may not be a direct precursor to invasive breast cancer. […] Current approaches for management of LCIS include surgical removal of the LCIS or treatment with anti-estrogens to reduce the risk of developing invasive cancer. […] Observation is a generally accepted form of management for patients with LCIS. […] Because of the observation that women with breast cancer treated with Nolvadex had a lower risk of developing a new breast cancer in their unaffected breast, many doctors felt that Nolvadex may actually be able to prevent breast cancer from occurring. […] In patients with LCIS, the incidence of invasive breast cancer was reduced 56% by the administration of Nolvadex.

• #49 Stage 0 Breast Cancer (DCIS, LCIS) – Cancer Therapy Advisor

  https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/oncology/stage-0-breast-cancer-dcis-lcis/

  The medical approach to LCIS is that of chemoprevention. Randomized clinical trials of chemoprevention in women at high risk for breast cancer have shown reduction in risk of invasive breast cancer for women with LCIS. In the NSABP Breast Cancer Prevention Trial-BCPT, tamoxifen reduced the risk of invasive cancer by 50% compared to placebo in those whose increased risk was due to LCIS. […] In the subsequent STAR trial, comparing tamoxifen to raloxifene in high-risk women, raloxifene was also found to be efficacious. However, in longer term follow-up, raloxifene was only 75% as effective as tamoxifen in reducing risk of breast cancer. […] In 2011, a study of chemoprevention with an aromatase inhibitor, exemestane was reported. In a median follow-up of 3 years, breast cancer events were reduced by over 50% with exemestane compared to placebo. The risk of invasive breast cancer was reduced by 65%.

• #50 Understanding lobular carcinoma in situ (LCIS) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/pre-cancerous-and-genetic-conditions/lobular-carcinoma-in-situ

  Lobular carcinoma in situ (LCIS) is not a cancer. But it can increase the risk of developing cancer. […] LCIS is not cancer. But it can increase the risk of breast cancer later in life. […] If you have LCIS, you will not need any treatment. LCIS usually does not cause any problems. Most people with LCIS do not develop breast cancer, so they never need treatment. You will be offered regular monitoring. This is to make sure that if a cancer develops, it is found early. […] Hormonal therapy is usually given to people who have had treatment for breast cancer. It aims to reduce the risk of cancer coming back. If you have LCIS, you may be offered hormonal therapy drugs to reduce the risk of breast cancer developing. […] Some women who are assessed as having a high risk of breast cancer, may think about having surgery to remove both breasts removed. This is to reduce the risk of breast cancer developing. It is called risk-reducing breast surgery. It is important to talk to your doctor about the potential risks and benefits before making a decision.

• #51 The Challenges of Treating Lobular Carcinoma In Situ

  https://www.cancernetwork.com/view/challenges-treating-lobular-carcinoma-situ

  Broadly stated, there are two main areas of research that could help refine the current management of LCIS. The first is development of the ability to define at diagnosis those LCIS lesions that are precursor lesions and that are likely to progress to invasive lobular cancers. […] The second research area involves the generation of risk estimates for invasive breast cancer among younger women diagnosed with LCIS. […] Lastly, it appears that the potential benefit of chemoprevention agents such as tamoxifen in women with LCIS has been underappreciated. […] Therefore, in women with LCIS, physicians should consider recommending tamoxifen in those who are premenopausal but post-childbearing and in those who are postmenopausal; they should also consider recommending exemestane (after it is FDA-approved) in postmenopausal women, provided they have no contraindications to therapy. […] Therefore, a woman’s risk should be reassessed periodically so that decisions regarding screening and risk-reduction approaches can be optimized.

• #52 Lobular Carcinoma in situ (LCIS) in Dallas, TX | Dallas Surgical GroupAccessibility ToolsIncrease TextDecrease TextGrayscaleHigh ContrastNegative ContrastLight BackgroundLinks UnderlineReadable FontReset

  https://dallassurgicalgroup.com/lobular-carcinoma-in-situ-lcis/

  LCIS does not develop into cancer itself, however, there is a ~25% risk of developing breast cancer in either breast over 30 years. Most of the cancers that do develop are ductal carcinoma (not invasive lobular carcinoma) and it can occur in any area of the breast. This means that there is no reason to try and remove all of it surgically. Therefore, the approach to LCIS is the same as for any woman who is at high risk – prevention of breast cancer. […] Prophylactic mastectomy is a viable option and will reduce the risk of developing breast cancer by at least 90%. Tamoxifen or raloxifene has been shown in a large study to reduce the chance of getting breast cancer by ~50%. The prevention study was not without side effects, however, and anyone considering this approach should weigh the risks and benefits for her age. Close follow up means having breast exams every six months and annual mammograms. There is no urgency to your decision regarding treatment of LCIS, as the risk stretches out over thirty years and does not begin immediately. Which path you choose will depend on your age, health, and values.

Zobacz więcej